Pharvaris N.V. Insider Trading
PHVS
Insiders sold $33M and bought nothing on the open market.
48% of the selling was scheduled in advance under 10b5-1 plans. Director Johannes Gerardus Christiaan Petrus Schikan sold $7M on Sep 17, 63% of their stake, outside a plan. No executive or director has bought shares on the open market in the last two years.
Get an email when PHVS's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Sep 23 | Viviane Monges Director | SoldNo plan | 11,969 | $33.05 | 396K | 69% | Form 4 |
| Sep 22 | Johannes Gerardus Christiaan Petrus Schikan Director | SoldNo plan | 800 | $36.19 | 29K | 0.7% | Form 4 |
| Sep 21 | David W. Nassif CFO / CLO | SoldNo plan | 6,000 | $36.47 | 219K | 5.0% | Form 4 |
| Sep 17 | Peng Lu President | SoldNo plan | 100,000 | $35.00 | $3.5M | 61% | Form 4 |
| Sep 17 | Johannes Gerardus Christiaan Petrus Schikan Director | SoldNo plan | 200,000 | $35.00 | $7M | 63% | Form 4 |
| Sep 17 | Elisabeth Bjork Director | SoldNo plan | 52,500 | $37.89 | $1.99M | 78% | Form 4 |
| Sep 17 | Robert Glassman Director | Sold10b5-1 plan | 14,493 | $38.56 | 559K | 58% | Form 4 |
| Sep 17 | Anne Lesage Chief Early Development | SoldNo plan | 20,000 | $38.27 | 765K | 13% | Form 4 |
| Sep 15 | Stefan Andreas Abele Chief Technical Ops Officer | SoldNo plan 2 parts | 46,400 | $38.17 average | $1.77M | 54% | Form 4 |
| Sep 15 | Robert Glassman Director | Sold10b5-1 plan | 8,667 | $38.27 | 332K | 45% | Form 4 |
| Sep 14 – 15 | Wim Souverijns Chief Commercial Officer | Sold10b5-1 plan 2 parts | 26,090 | $39.24 average | $1.02M | 40% | Form 4 |
| Sep 14 | Berndt Modig Chief Executive Officer | Sold10b5-1 plan | 2,291 | $39.40 | 90K | 0.2% | Form 4 |
| Sep 11 | Peng Lu President | Sold10b5-1 plan | 15,000 | $40.13 | 602K | 19% | Form 4 |
| Sep 10 | Anne Lesage Chief Early Development | Sold10b5-1 plan | 30,000 | $38.30 | $1.15M | 35% | Form 4 |
| Sep 9 | Robert Glassman Director | Sold10b5-1 plan | 8,000 | $37.55 | 300K | 43% | Form 4 |
| Sep 8 | Peng Lu President | Sold10b5-1 plan | 15,000 | $40.68 | 610K | 19% | Form 4 |
| Aug 14 | Berndt Modig Chief Executive Officer | Sold10b5-1 plan | 2,292 | $34.77 | 80K | 0.2% | Form 4 |
| Jul 13 | Berndt Modig Chief Executive Officer | Sold10b5-1 plan | 2,292 | $34.97 | 80K | 0.2% | Form 4 |
| Jun 29 – 30 | Johannes Gerardus Christiaan Petrus Schikan Director | Sold10b5-1 plan 2 parts | 37,600 | $35.41 average | $1.33M | 11% | Form 4 |
| Jun 29 – 30 | Anne Lesage Chief Early Development | Sold10b5-1 plan 5 parts | 76,172 | $35.39 average | $2.7M | 33% | Form 4 |
| Jun 29 | Johannes Gerardus Christiaan Petrus Schikan Director | Sold10b5-1 plan | 2,400 | $35.10 | 84K | 0.7% | Form 4 |
| Jun 25 – 26 | Peng Lu Chief Medical Officer | Sold10b5-1 plan 3 parts | 29,700 | $34.30 average | $1.02M | 31% | Form 4 |
| Jun 25 | Anne Lesage Chief Early Development | Sold10b5-1 plan 2 parts | 4,600 | $35.12 average | 162K | 2.4% | Form 4 |
| Jun 18 | Peng Lu Chief Medical Officer | Sold10b5-1 plan | 300 | $34.00 | 10K | 0.5% | Form 4 |
| Jun 15 | Berndt Modig Chief Executive Officer | Sold10b5-1 plan 2 parts | 2,291 | $31.07 average | 71K | 0.2% | Form 4 |
| Jun 4 | Anna Nijdam Principal Accounting Officer | SoldNo plan | 2,670 | $30.87 | 82K | 5.5% | Form 4 |
| May 21 – 22 | Anna Nijdam Principal Accounting Officer | SoldNo plan 2 parts | 7,330 | $30.71 average | 225K | 13% | Form 4 |
| May 21 | Viviane Monges Director | SoldNo plan | 9,667 | $30.29 | 293K | 64% | Form 4 |
| May 21 | David W. Nassif CFO / CLO | SoldNo plan | 10,000 | $30.31 | 303K | 7.7% | Form 4 |
| May 20 | Elisabeth Bjork Director | Sold10b5-1 plan | 10,000 | $29.32 | 293K | 40% | Form 4 |
| May 18 | Berndt Modig Chief Executive Officer | Sold10b5-1 plan | 2,292 | $29.22 | 67K | 1.6% | Form 4 |
| May 15 | Robert Glassman Director | SoldNo plan 2 parts | 10,000 | $29.83 average | 298K | 49% | Form 4 |
| May 15 | Stefan Andreas Abele Chief Technical Ops Officer | SoldNo plan | 8,748 | $29.82 | 261K | 20% | Form 4 |
| May 15 | Wim Souverijns Chief Commercial Officer | Sold10b5-1 plan | 10,000 | $29.92 | 299K | 18% | Form 4 |
| May 1 | Peng Lu Chief Medical Officer | Sold10b5-1 plan 2 parts | 14,166 | $30.17 average | 427K | 18% | Form 4 |
| Apr 29 – 30 | Johannes Gerardus Christiaan Petrus Schikan Director | Sold10b5-1 plan 3 parts | 32,900 | $30.29 average | 996K | 8.5% | Form 4 |
| Apr 29 – 30 | Anne Lesage Chief Early Development | Sold10b5-1 plan 5 parts | 48,300 | $30.23 average | $1.46M | 20% | Form 4 |
| Apr 29 – 30 | Peng Lu Chief Medical Officer | Sold10b5-1 plan 2 parts | 18,733 | $30.20 average | 566K | 22% | Form 4 |
| Apr 22 – 23 | Johannes Gerardus Christiaan Petrus Schikan Director | Sold10b5-1 plan 2 parts | 7,100 | $30.05 average | 213K | 1.8% | Form 4 |
| Apr 22 – 23 | Anne Lesage Chief Early Development | Sold10b5-1 plan 5 parts | 14,700 | $30.05 average | 442K | 6.4% | Form 4 |
- Sep 23No planViviane MongesDirector · sold 11,969 at $33.05396K69% of stake
- Sep 22No planJohannes Gerardus Christiaan Petrus SchikanDirector · sold 800 at $36.1929K0.7% of stake
- Sep 21No planDavid W. NassifCFO / CLO · sold 6,000 at $36.47219K5.0% of stake
- Sep 17No planPeng LuPresident · sold 100,000 at $35.00$3.5M61% of stake
- Sep 17No planJohannes Gerardus Christiaan Petrus SchikanDirector · sold 200,000 at $35.00$7M63% of stake
- Sep 17No planElisabeth BjorkDirector · sold 52,500 at $37.89$1.99M78% of stake
- Sep 1710b5-1 planRobert GlassmanDirector · sold 14,493 at $38.56559K58% of stake
- Sep 17No planAnne LesageChief Early Development · sold 20,000 at $38.27765K13% of stake
- Sep 15No planStefan Andreas AbeleChief Technical Ops Officer · sold 46,400 at avg $38.17$1.77M54% of stake
- Sep 1510b5-1 planRobert GlassmanDirector · sold 8,667 at $38.27332K45% of stake
- Sep 14 – 1510b5-1 planWim SouverijnsChief Commercial Officer · sold 26,090 at avg $39.24$1.02M40% of stake
- Sep 1410b5-1 planBerndt ModigChief Executive Officer · sold 2,291 at $39.4090K0.2% of stake
- Sep 1110b5-1 planPeng LuPresident · sold 15,000 at $40.13602K19% of stake
- Sep 1010b5-1 planAnne LesageChief Early Development · sold 30,000 at $38.30$1.15M35% of stake
- Sep 910b5-1 planRobert GlassmanDirector · sold 8,000 at $37.55300K43% of stake
- Sep 810b5-1 planPeng LuPresident · sold 15,000 at $40.68610K19% of stake
- Aug 1410b5-1 planBerndt ModigChief Executive Officer · sold 2,292 at $34.7780K0.2% of stake
- Jul 1310b5-1 planBerndt ModigChief Executive Officer · sold 2,292 at $34.9780K0.2% of stake
- Jun 29 – 3010b5-1 planJohannes Gerardus Christiaan Petrus SchikanDirector · sold 37,600 at avg $35.41$1.33M11% of stake
- Jun 29 – 3010b5-1 planAnne LesageChief Early Development · sold 76,172 at avg $35.39$2.7M33% of stake
- Jun 2910b5-1 planJohannes Gerardus Christiaan Petrus SchikanDirector · sold 2,400 at $35.1084K0.7% of stake
- Jun 25 – 2610b5-1 planPeng LuChief Medical Officer · sold 29,700 at avg $34.30$1.02M31% of stake
- Jun 2510b5-1 planAnne LesageChief Early Development · sold 4,600 at avg $35.12162K2.4% of stake
- Jun 1810b5-1 planPeng LuChief Medical Officer · sold 300 at $34.0010K0.5% of stake
- Jun 1510b5-1 planBerndt ModigChief Executive Officer · sold 2,291 at avg $31.0771K0.2% of stake
- Jun 4No planAnna NijdamPrincipal Accounting Officer · sold 2,670 at $30.8782K5.5% of stake
- May 21 – 22No planAnna NijdamPrincipal Accounting Officer · sold 7,330 at avg $30.71225K13% of stake
- May 21No planViviane MongesDirector · sold 9,667 at $30.29293K64% of stake
- May 21No planDavid W. NassifCFO / CLO · sold 10,000 at $30.31303K7.7% of stake
- May 2010b5-1 planElisabeth BjorkDirector · sold 10,000 at $29.32293K40% of stake
- May 1810b5-1 planBerndt ModigChief Executive Officer · sold 2,292 at $29.2267K1.6% of stake
- May 15No planRobert GlassmanDirector · sold 10,000 at avg $29.83298K49% of stake
- May 15No planStefan Andreas AbeleChief Technical Ops Officer · sold 8,748 at $29.82261K20% of stake
- May 1510b5-1 planWim SouverijnsChief Commercial Officer · sold 10,000 at $29.92299K18% of stake
- May 110b5-1 planPeng LuChief Medical Officer · sold 14,166 at avg $30.17427K18% of stake
- Apr 29 – 3010b5-1 planJohannes Gerardus Christiaan Petrus SchikanDirector · sold 32,900 at avg $30.29996K8.5% of stake
- Apr 29 – 3010b5-1 planAnne LesageChief Early Development · sold 48,300 at avg $30.23$1.46M20% of stake
- Apr 29 – 3010b5-1 planPeng LuChief Medical Officer · sold 18,733 at avg $30.20566K22% of stake
- Apr 22 – 2310b5-1 planJohannes Gerardus Christiaan Petrus SchikanDirector · sold 7,100 at avg $30.05213K1.8% of stake
- Apr 22 – 2310b5-1 planAnne LesageChief Early Development · sold 14,700 at avg $30.05442K6.4% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Biotechnology · Pick stocks to compare with PHVS
Held by ETFs
PHVS is in 16 US ETFs. The largest of them, with PHVS's weight in each:
Fidelity Nasdaq Composite Index ETFONEQ0.01%of the fund
iShares Biotechnology ETFIBB0.07%of the fund
iShares Core MSCI Europe ETFIEUR0.00%of the fund
iShares U.S. Small-Cap Equity Factor ETFSMLF0.01%of the fund
iShares MSCI Netherlands ETFEWN0.25%of the fund
iShares MSCI Europe Small-Cap ETFIEUS0.05%of the fund
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PHVS
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.